1. ORIC will present data on enozertinib at ESMO Asia Congress 2025. 2. Presentations focus on NSCLC patients with specific EGFR mutations. 3. Key oral presentations scheduled for December 5 and 6, 2025. 4. Conference call for stakeholders will happen after the presentations. 5. ORIC's pipeline includes other promising oncology candidates.
FAQ
Why Bullish?
The positive data from clinical trials can bolster investor confidence, similar to previous cases where trial results enhanced stock value.
How important is it?
The upcoming presentations and conference call could significantly affect market perceptions and investor actions.
Why Short Term?
Immediate effects expected post-presentation, mirroring past scenarios where trial announcements have led to swift stock movement.
ORIC Pharmaceuticals Unveils Late-Breaking Presentations of Enozertinib (ORIC-114) at ESMO Asia Congress 2025
SOUTH SAN FRANCISCO and SAN DIEGO, December 3, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical-stage oncology company, has announced two significant late-breaking oral presentations featuring data from a Phase 1b trial of enozertinib (ORIC-114). These presentations will take place at the ESMO Asia Congress 2025, scheduled for December 5-7, 2025, in Singapore.
Presentation Overview
The upcoming presentations will cover crucial findings regarding the efficacy of enozertinib in treating non-small cell lung cancer (NSCLC) associated with specific EGFR mutations:
-
Mini-Oral Presentation:
- Title: Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor, in Previously Treated NSCLC with EGFR Atypical Mutations: Randomized Dose Optimization and CNS Activity
- Presentation Number: LBA15
- Session Type: Mini Oral session 1: Thoracic malignancies
- Date & Time: Friday, December 5, 2025; 11:38 – 11:43 a.m. SGT
-
Proffered Paper Oral Presentation:
- Title: Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor, in EGFR Exon 20 Mutant NSCLC: Randomized Dose Optimization and CNS Activity
- Presentation Number: LBA13
- Session Type: Proffered Paper session: Thoracic malignancies
- Date & Time: Saturday, December 6, 2025; 10:02 – 10:12 a.m. SGT
Full abstracts highlighting these late-breaking presentations will be accessible on the ESMO Asia Congress website.
Conference Call and Webcast
ORIC Pharmaceuticals will also host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET, coinciding with the congress. Participants wishing to join the call must pre-register online to receive the relevant telephone number and unique passcode. The webcast will be archived on ORIC’s investor relations page, with replays available for 90 days following the event.
About ORIC Pharmaceuticals
ORIC Pharmaceuticals is dedicated to advancing therapeutics that address resistance mechanisms in cancer. The company's key product candidates include:
- ORIC-944: An allosteric inhibitor of the polycomb repressive complex 2 (PRC2) for prostate cancer.
- Enozertinib (ORIC-114): A brain-penetrant inhibitor targeting EGFR exon 20, EGFR atypical, and HER2 exon 20 mutations across genetically defined cancers.
With offices in South San Francisco and San Diego, California, ORIC is committed to improving patient outcomes. For detailed information, visit www.oricpharma.com and connect with us on social media platforms such as X and LinkedIn.
Contact Information
For media inquiries or additional information, please contact:
Dominic Piscitelli
Chief Financial Officer
Email: dominic.piscitelli@oricpharma.com
General Inquiries: info@oricpharma.com